Table 3.
T cell activation using RNA-transfected dendritic cells
| Study | Type of RNA | Transfection | Activation |
|---|---|---|---|
| Nair et al. [18] | CEA RNA | PP/LIPO | CD8+/CD4+ |
| Thornburg et al. [29] | HPV E6, E7 RNA | LIPO | CD8+ |
| Heiser et al. [30] | PSA RNA | PP | CD8+ |
| Weissman et al.[31] | HIV gag RNA | LIPO | CD8+/CD4+ |
| Su et al. [28] | TERT RNA | LIPO | CD8+/CD4+ |
| Strobel et al. [19] | IMP RNA | LIPO | CD8+ |
| Ponsaerts et al. [21] | IMP RNA | EP | CD8+ |
| Ponsaerts et al. [32] | IMP RNA | EP | CD8+ |
| Saebφe-Larssen et al. [22] | TERT RNA | EP | CD8+ |
| Kalady et al. [23] | Melan-A RNA | EP | CD8+ |
| Heiser et al.[33] | Total renal tumour RNA | PP | CD8+ |
| Heiser et al. [35] | Prostate tumour RNA (Ampl.) | PP | CD8+ |
| Milazzo et al. [36] | Total myeloma RNA | EP | CD8+ |
Type of RNA: CEA, carcino-embryonic antigen; HPV, human papillomavirus; PSA, prostate specific antigen; HIV, human immunodeficiency virus; TERT, telomerase; IMP, influenza matrix protein; Melan-A, melanoma antigen; Ampl., amplified. Transfection: PP, passive pulsing; LIPO, lipofection, EP, electroporation.